Tmunity Therapeutics

About:

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells.

Website: https://www.tmunity.com

Twitter/X: tmunitytx

Top Investors: Andreessen Horowitz, University of Pennsylvania, Kleiner Perkins, Gilead Sciences, Parker Institute for Cancer Immunotherapy

Description:

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.